Research programme: central nervous system therapeutics - ArmaGen

Drug Profile

Research programme: central nervous system therapeutics - ArmaGen

Alternative Names: AGT-110; AGT-115; AGT-120; AGT-160; AGT-185; AGT-190; AGT-3; AGT-3100; AGT-m110; AGT-m115; Rett fusion protein - ArmaGen; Rett syndrome therapeutic - ArmaGen

Latest Information Update: 01 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ArmaGen Technologies
  • Class Antibodies; Enzymes; Erythropoietins; Gene therapies; Immunoglobulin fusion proteins
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Erythropoietin receptor agonists; Glial cell line-derived neurotrophic factor agonists; Neuron stimulants; Protein replacements; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor decoy receptor modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease; Poisoning; Stroke
  • Research Rett syndrome
  • No development reported Brain cancer; Brain disorders; Major depressive disorder; Spinal cord injuries

Most Recent Events

  • 24 Nov 2016 Preclinical trials in Amyotrophic lateral sclerosis in USA (IV) (ArmaGen Technologies pipeline, November 2016)
  • 07 Jul 2016 ArmaGen and Rett Syndrome Research Trust agree to co-develop therapeutics for Rett syndrome
  • 07 Jul 2016 Early research in Rett syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top